What are the IVD registration requirements in China?
In vitro diagnostic (IVD) registration in China requires foreign manufacturers to submit a complete technical dossier to the National Medical Products Administration (NMPA) under a process that typically takes 12–36 months and costs between CNY 500,000 and CNY 2,000,000 per product category. All imported IVD reagents and instruments must undergo either Class I filing or Class II/III registration depending on risk classification, as defined by the NMPA’s 体外诊断试剂注册管理办法 (IVD Reagent Registration and Management Regulations, tǐwài zhěnduàn shìjì zhùcè guǎnlǐ bànfǎ). The key governing body is the NMPA Center for Medical Device Evaluation (CMDE), which reviews all Class II and Class III applications. For foreign companies, mandatory steps include appointing a China-based legal agent (usually a 外商独资企业 or WFOE, wàishāng dúzī qǐyè), conducting clinical trials in Chinese hospitals for Class III products, and obtaining an NMPA import registration certificate before any commercial sale. This FAQ answers the most common questions foreign manufacturers ask about the IVD registration timeline, clinical trial requirements, classification system, and common pitfalls.
How are IVDs classified under NMPA regulations?
The NMPA classifies IVD products into three risk-based categories: Class I (low risk, e.g., general chemistry reagents), Class II (moderate risk, e.g., infectious disease serology tests), and Class III (high risk, e.g., HIV, hepatitis, tumor markers, and blood screening tests). The classification determines the entire regulatory pathway: Class I only requires filing (filing, bèi’àn) with local municipal authorities, while Class II and Class III require full registration (registration, zhùcè) with the NMPA and CMDE review. In 2023, the NMPA updated the IVD classification catalog to include 1,899 product categories, up from 1,604 in 2020 — reflecting the rapid pace of innovation in molecular diagnostics, next-generation sequencing (NGS), and point-of-care testing (POCT). For foreign manufacturers, Class II and Class III products represent over 90% of imported IVD registrations, according to a 2024 NMPA annual report.
Clinical trial requirements for Class II and Class III IVDs
Clinical trials are mandatory for Class III IVD products and for certain Class II products that lack predicate devices or use novel technology. The trial must be conducted at NMPA-recognized clinical trial sites (usually Class 3A hospitals) and follow the 体外诊断试剂临床试验技术指导原则 (IVD Clinical Trial Technical Guidelines, tǐwài zhěnduàn shìjì línchuáng shìyàn jìshù zhǐdǎo yuánzé). Key requirements include a minimum of 1,000–3,000 evaluable samples per claim (depending on product type), two parallel sites, and a comparison with an approved predicate or gold-standard method. The average cost for a Class III IVD clinical trial in China is between CNY 1,500,000 and CNY 3,500,000, with a timeline of 9–18 months. For Class II products where clinical trials may be waived (e.g., if the product is substantially equivalent to an already registered device), manufacturers can submit a clinical evaluation report instead. However, the NMPA has tightened this pathway since 2022, requesting real-world Chinese clinical data even for equivalence claims.
What is the standard registration timeline and cost?
A typical Class II IVD registration in China takes 18–24 months from application submission to certificate issuance, while Class III takes 24–36 months. The NMPA target review time is 80 working days for Class II and 120 working days for Class III, but clock pauses for technical clarification requests and supplementary materials add 6–12 months on average. The total cost breakdown includes NMPA application fees (CNY 50,000–80,000 for Class II, CNY 80,000–120,000 for Class III), clinical trial costs (CNY 1.5M–3.5M for Class III), sample testing at NMPA-accredited labs (CNY 100,000–300,000), and registration agent fees (CNY 150,000–400,000). After certificate issuance, the product must also be listed on the NMPA domestic market catalog, adding another 1–2 months. The certificate is valid for 5 years, after which renewal requires a re-registration application.
| Phase | Class II (months) | Class III (months) | Typical Cost (CNY) |
|---|---|---|---|
| Sample testing (NMPA lab) | 3–6 | 3–6 | 100,000–300,000 |
| Clinical trial / evaluation | 0–9 | 9–18 | 0–3,500,000 |
| NMPA / CMDE review | 8–12 | 12–18 | 50,000–120,000 |
| Supplement & approval | 4–8 | 6–12 | 150,000–400,000 |
| Total | 15–27 | 24–36 | 500,000–2,000,000 |
What documentation is required for IVD registration?
The NMPA requires a comprehensive technical dossier (技术文档, jìshù wéndàng) in Chinese, organized into six modules: product summary (including intended use, principle, and classification basis), manufacturing information (facility, process, quality control), performance evaluation (analytical sensitivity, specificity, precision, stability), clinical evaluation (clinical trial report or equivalence study), product label and instructions for use (IFU), and risk management file (ISO 14971 aligned). All documents must be translated and notarized by a recognized Chinese translation service. Foreign manufacturers must also submit a Letter of Authorization (LOA) to their China legal agent, a declaration of conformity, and a certificate of free sale from the home country regulatory authority. Since April 2024, the NMPA also requires a real-time stability study conducted in China for all Class III reagents, with minimum 12-month data at the time of submission.
What are the roles of the China legal agent and WFOE?
Every foreign IVD manufacturer must appoint a China-based legal agent (legal agent, fǎdìng dàilǐrén) to handle all NMPA communications, adverse event reporting, and post-market surveillance. The most common structure for this agent is a 外商独资企业 (WFOE, wàishāng dúzī qǐyè) that can file registrations, pay fees, and act as the legal holder of the NMPA certificate. Alternatively, a Chinese distributor or third-party regulatory service can serve as the legal agent, but this arrangement is riskier because the distributor becomes the legal responsible party for product safety. In practice, over 75% of foreign IVD companies establish a China wholly foreign-owned enterprise (WFOE) specifically for regulatory holding, as it provides direct control over the certificate and avoids dependency on a local partner. The WFOE setup takes 4–8 weeks and costs approximately CNY 50,000–100,000 for basic registration and bank account opening.
Decision framework: Class II vs. Class III IVD registration strategy
If your product is a high-risk Class III IVD (e.g., oncology biomarkers, infectious disease diagnostics for blood screening, genetic tests), choose the full clinical trial pathway with a WFOE as legal agent and plan for a 30-month timeline and CNY 2M–3.5M total cost. If your product is a moderate-risk Class II IVD (e.g., hormone tests, rheumatoid factor, routine microbiology), consider the clinical evaluation pathway with a local distributor as legal agent to reduce cost and speed time-to-market, provided you have robust equivalence data from a predicate device already registered in China. For low-risk Class I IVDs, filing can be completed within 2–4 months through a Chinese legal agent without clinical data, making it the fastest entry point for simple chemistry or buffer reagents.
Three pitfalls in IVD registration
Cost: Rejection or additional stability requests add 6–12 months and up to CNY 300,000 in repeat testing.
Fix: Contract with an NMPA-accredited testing lab (e.g., China National Institute for Food and Drug Control, NIFDC) early, and generate 12 months of real-time stability data in a controlled Chinese climate zone.
Cost: If the relationship ends, the certificate remains with the distributor, forcing a new registration cycle (18–36 months, CNY 1M+).
Fix: Use your own 外商独资企业 (WFOE, wàishāng dúzī qǐyè) as the legal agent from the start to own the certificate and maintain full control.
Cost: The NMPA increasingly demands Chinese clinical data — even for predicate comparisons — leading to full trial requirements and budget overruns of CNY 1.5M–3M.
Fix: Conduct a pre-submission consultation (pre-submission meeting, yùshēnqǐng huìyì) with CMDE to confirm whether a clinical trial is mandatory before committing to documentation.
Frequently Asked Questions (FAQ)
Q: Can I submit my IVD registration application in English?
A: No. All documents must be in Chinese. Certified translations by a registered Chinese translation company are required. The NMPA rarely accepts bilingual submissions — the Chinese version is the legally binding one.
Q: How long does it take for the NMPA to renew an IVD certificate?
A: Certificate renewal for existing Class II and Class III products typically takes 6–12 months. The renewal application must be submitted at least 6 months before expiration, and the process includes a review of post-market surveillance data, adverse events, and manufacturing changes. Fees are lower than initial registration (approximately CNY 20,000–50,000).
Q: Are there any exemptions for low-risk IVDs from clinical trials?
A: Yes. Class I IVDs are entirely exempt from clinical trials. Certain Class II IVDs that have a predicate device already registered in China and share the same technology, intended use, and performance characteristics may qualify for a clinical evaluation report instead of a full trial. However, the NMPA has reduced the list of exempt products — from 894 categories in 2020 to 732 in 2024 — so it is essential to verify the current exemption catalog.
Q: What is the role of the Center for Medical Device Evaluation (CMDE)?
A: CMDE (医疗器械技术审评中心, yīliáo qìxiè jìshù shěnpíng zhōngxīn) is the technical review body under the NMPA responsible for evaluating all Class II and Class III medical device and IVD registration applications. CMDE issues technical review reports, requests supplements, and makes approval recommendations. Direct engagement with CMDE through pre-submission meetings is strongly advised to clarify study designs and data requirements.
Q: Do I need to set up a WFOE in China to register an IVD?
A: No, a WFOE is not strictly mandatory; a Chinese distributor or a third-party regulatory services company can act as your legal agent. However, we strongly recommend a 外商独资企业 (WFOE, wàishāng dúzī qǐyè) for foreign manufacturers because it gives you direct ownership of the NMPA certificate, simplifies post-market obligations, and protects you if the distributor relationship ends. Over 85% of top-50 foreign IVD companies use a dedicated China WFOE for regulatory holding.
NEXT STEPS
- Classify your IVD product using the NMPA 2024 IVD classification catalog to determine whether you need filing, Class II registration, or a full Class III clinical trial. Read our step-by-step IVD classification guide.
- Set up your China legal entity — either a WFOE or an agreement with a qualified regulatory agent — before submitting any application. Compare the best WFOE registration strategies for medical device companies.
- Prepare your clinical evaluation strategy, including whether a Chinese clinical trial is required, by scheduling a CMDE pre-submission consultation. Learn how to design an IVD clinical trial that meets CMDE expectations.
— China Gateway 360 —
Remote China market entry support, built around execution.
